Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fotemustine and Dacarbazine +/- Interferon in Advanced Melanoma
NCT01359956Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2002
- Primary completion
- Feb 2011
- Modality
- Cytokines & Interferons, Small Molecules
01
Overview
Phase 3, randomised trial of fotemustine and interferon alfa-2b in Malignant Melanoma (MM) (4 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Survival at 24 months. Started Apr 2002; status: completed.
02
Drugs
fotemustineinterferon alfa-2b
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT01359956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01359956.